Drug Profile
Research programme: cancer therapeutics and diagnostics - Georgetown University/Samaritan
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Georgetown University
- Developer Samaritan Pharmaceuticals
- Class Diagnostic agents
- Mechanism of Action Diagnostic imaging enhancers; GABA A receptor agonists; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA
- 23 Aug 2007 Preclinical trials in Cancer diagnosis in USA (unspecified route)